J Renal Inj Prev. 2017;6(1): 18-25. doi: 10.15171/jrip.2017.04
PMID: 28487867        PMCID: PMC5414514

Case Report

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy

Cited by CrossRef: 3

1- Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M, Ariga T. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol. 2019;34(1):87 [Crossref]
2- Desai A, Noor A, Joshi S, Kim A. Takotsubo cardiomyopathy in cancer patients. Cardio-Oncology. 2019;5(1) [Crossref]
3- Farkas A, Marcott M, Yanta J, Pizon A. Bicarbonate refractory QRS prolongation and left bundle‐branch block following escitalopram and lamotrigine overdose: A case report and literature review of toxic left bundle‐branch block. J Clin Pharm Ther. 2018;43(5):717 [Crossref]
4- Gumerova K, Sakhautdinova G, Polyakova I. Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods. Kreativnaâ hirurgiâ i onkologiâ. 2020;9(4):285 [Crossref]
5- Pozdzik A, Brochériou I, David C, Touzani F, Goujon J, Wissing K. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. BioMed Research International. 2018;2018:1 [Crossref]
6- Bayer G, Agier M, Lioger B, Lepelley M, Zenut M, Lanoue M, Maillot F, Jonville-Bera A. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European Journal of Internal Medicine. 2019;67:59 [Crossref]
7- Aimo A, Tavoni A, Buda G, Emdin M, Dinov B, Asher E, Musella F, Tan T. Rituximab as a novel treatment for heart failure: evidence from a case series. 2019;3(4):1 [Crossref]